Business Context and Reporting Period
Company: Pro-Pharmaceuticals, Inc. (Note: Metadata listed "Galectin Therapeutics Inc," but the filing text identifies the registrant as Pro-Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 30, 2010 (Event Date); Signed January 6, 2011
Principal Activity: The Company entered into Subscription Agreements to issue and sell Series C Super Dividend Convertible Preferred Stock to raise capital.
Key Financial Metrics
- Gross Proceeds: $2,120,000 from the sale of 212 shares of Series C Preferred Stock at $10,000 per share.
- Cash Position: Approximately $6.3 million as of January 5, 2011 (per press release referenced in Item 2.02).
- Revenue/Profit/Margins: The filing text does not provide specific revenue, profit, or margin figures for the period.
- Debt: No specific debt figures are provided in this filing.
Material Changes
The primary material change is the completion of a private placement of equity securities. The Company issued 212 shares of Series C Super Dividend Convertible Preferred Stock. This transaction increased the Company's cash reserves and altered its capital structure by introducing a new class of preferred stock with specific dividend and conversion rights.
Terms, Outlook, and Risks
Terms of Series C Preferred Stock
- Dividends: Cumulative non-compounding dividends at the greater of 6% per annum or a percentage of net sales from the DAVANAT® product (2.5% until total investment is returned, then 1.25%). Dividends may be paid in cash or common stock.
- Conversion: Convertible into Common Stock at $1.00 per share. The Company may force conversion if the Common Stock closes at or above $3.00 for 15 consecutive trading days.
- Liquidation Preference: $10,000 per share plus accrued dividends, subordinate to Series A, B-1, and B-2 Preferred Stock but senior to Common Stock.
- Redemption: In the event of a sale of the Company, shares are redeemable at a price based on an incremental return on investment percentage minus cumulative dividends received.
- Maximum Payout: Dividends are capped at an aggregate value of $100,000 per share.
Risks and Contingencies
- Dilution: Conversion of preferred stock and payment of dividends in common stock will dilute existing common shareholders.
- Dividend Obligation: The Company has a continuing obligation to pay dividends, which may impact cash flow if paid in cash.
- Unregistered Sale: Shares were sold under Section 4(2) and Rule 506 exemptions; no underwriting discounts were paid.
Investor Verification Checklist
- Verify the current cash balance and burn rate to assess runway given the $6.3 million cash position reported in early January 2011.
- Review the net sales figures for the DAVANAT® product to calculate the potential dividend obligation under the sales-based formula.
- Confirm the current trading price of Common Stock to evaluate the likelihood of forced conversion (triggered at $3.00).
- Examine the full text of the Certificate of Designation (Exhibit 3.1) for specific details on the "incremental return on investment percentage" used in redemption calculations.
- Check for any subsequent filings regarding the payment of accrued dividends or conversion of Series C shares.